A legal entity created on a voluntary basis and engaged in a certain business, company can operate in different market and counties. A company size is measured on the basis of its market value, sales, assets or profits. As a rule, companies are represented by the following types: be private, public, government, unlimited, foreign, producer, to name a few. Typical departments found in almost any company comprise but are not limited to production, customer services, marketing, human resources, finance, to name a few.
Exxon Mobil, JPMorgan Chase, Shell, Apple, Royal Dutch Shell and Toyota Motor are amidst the globe’s largest and most influential companies, with most of them active the world over.
This Catalogue’s research reports cover companies involved in various business activities, be it production, sales, marketing, etc. The reports contain information on companies’ activities, historical development, key executives, departments, product offerings. SWOT analyses, data on market share, marketing strategies, the most recent activities within the industry, acquisitions, strategic partnerships and alliances are included in the research reports.
Publications found:
193,061
Sort by:
MORPHOSYS (MOR) - MOR103/ MOR202 - Partnering is the Beginning of a New Phase of Growth
US$ 140.00
Alliances with GSK and Celgene in 2013 propelled MorphoSys (MOR) in the limelight. This could well be the inflection point in MorphoSys's evolution into a successful mature ... , please read our report released on September 12, 2013, titled, “MOR103/ MOR202 – Partnering is the Beginning of a New Phase of Growth ”.
September 2013
5 pages
Generic Advair - 3 years to go, but which generic companies are better poised?
US$ 140.00
... announced the draft guidance for the development of generic version of GSK’s Asthma / COPD drug – Advair (Fluticasone propionate + Salmeterol Xinafoate). The ... guidelines pave the way for generic companies to launch a substitutable and interchangeable version of Advair in the US market, which should ...
September 2013
3 pages
Vedolizumab, MLN0002, Ulcerative colitis, Crhon's disease, integrin inhibitor, Remicade, Humira, Simponi, Tysabri, Etrolizumab, Tofacitinib, GEMINI 1,2, STELARA, GSK-1605786, Vercirnon, Traficet-EN
US$ 250.00
Takeda received priority review status from US FDA for its late stage candidate Vedolizumab (filed for UC and Crhon’s disease (CD), a4ß7 integrin inhibitor) to treat ulcerative colitis indication. Vedolizumab targets the disease by preventing ...
September 2013
7 pages
Celgene (CELG) - Label Expansion of Marketed Product and Newly Drug launches + Maturing Pipeline = Long Term Gain
US$ 140.00
... Apremilast (PR, Psoriasis, PsA), and label and geographic expansion of marketed products – Revlimid, Vidaza, and ABRAXANE (L, mBC, NSCLC; R – pancreatic cancer, PDUFA: Sept. 21, 2013 ... detail please read our report on Celgene released on 2nd Sept. 2013, titled, "Label Expansion of Marketed Product and Newly Drug ...
September 2013
6 pages
Onconova Therapeutics (ONTX) -Near-Term Catalysts = Upside Still!
US$ 200.00
Onconova Therapeutics (ONTX) debut on NASDAQ (IPO: ... in pts with 2nd-line Higher Risk MDS vs. less than six months offered ... ). Our risk reward analysis indicates that ONTX's lead drug, Estybon (Rigosertib/ ON ... our report on Onconova released on 30th August 2013, titled, "Near-Term Catalysts = Upside Still!"
August 2013
11 pages
Amazon, QVC Inc., Sears Holding Corp, Valve Corp. -Company Analysis, SWOT, Marketing Strategy
US$ 750.00
... and return. The biggest player in the United States online retail market is Amazon.com and it is expected to remain a clear leader in the years to come. ... for mobile platforms as well. Renub Research study titled “Amazon, QVC Inc., Sears Holding Corp, Valve Corp. -Company Analysis, SWOT, Marketing Strategy” ...
August 2013
59 pages
KYORIN, Flutiform Will Make its Japanese Debut Soon - A game changer for Kyorin!
US$ 200.00
... PAFSC committee recommendation, Flutiform (Fluticasone propionate + formoterol) fixed dose combination is likely to get Japanese approval in September. It will be the third ... MDI (Chart 1) and Symbicort Trubohaler. Key advantage with Flutiform is its faster onset of action which gives rapid relief from ...
August 2013
5 pages
Annual Strategy Dossier - 2013-2014 - North America's 7 Leading Armored Vehicle Manufacturers - Key Strategies, Plans, SWOT, Trends & Strategic Outlook - General Dynamics Land Systems, BAE Systems, Oshkosh Corporation, Navistar Defense, Lockheed Martin, Textron Systems, AM General
US$ 1,295.00
... scenario. Most North American OEMs are working towards implementing an array of strategies and plans aimed at partially offsetting the ongoing spending cuts ... Perspective on the Business & Strategic Outlook for all key players for 2013-2014 Gaining access to Key Industry as well as Market Trends, Insights ...
August 2013
76 pages
Annual Strategy Dossier - 2013-2014 - World's 7 Leading Automotive OEMs - Key Strategies, Plans, SWOT, Trends & Strategic Outlook - GM, Toyota, Ford, Volkswagen, Daimler, BMW & Fiat
US$ 1,295.00
... for global leadership in terms of vehicle sales by 2018. 5. Analysis of Daimler & BMW’s strategies aimed at offsetting the ongoing European market slump by boosting sales ... SWOT Analysis & Strategic Outlook for all key players for 2013-2014 Gaining access to Key Industry as well as Market Trends, Insights & ...
August 2013
65 pages
Annual Strategy Dossier - 2013 - World's 10 Leading Construction Equipment Manufacturers - Key Strategies, Plans, SWOT, Trends & Strategic Outlook - Caterpillar, Komatsu, Volvo, Hitachi, Sany, John Deere, CNH, Sandvik, Terex, Kubota
US$ 1,995.00
... BRIC. 3. Analysis of John Deere’s 2018 Growth Strategy driven by BRIC Expansion & Capabilities Integration. 4. Analysis of Komatsu’s 2013-2016 Mid-Range Strategic Plan ... on the Business & Strategic Outlook for all key players for 2013 Gaining access to Key Industry as well as Market Trends, Insights & Growth ...
June 2013
108 pages
Annual Strategy Dossier - 2013 - World's 10 Leading Wheeled Armoured Vehicle Manufacturers - Key Strategies, Plans, Trends, Force Field Analysis & Strategic Outlook - General Dynamics Land Systems, BAE Systems, Oshkosh Corporation, Navistar Defense, Thales, Rheinmetall Defence, Nexter Systems, Iveco Defense Vehicles, Renault Defense Trucks, Textron Systems
US$ 1,657.00
... The European conditions are not good either with the French annual defense spending too, projected to stay flat at €31.4 billion through 2014- ... present macro-environmental uncertainty & difficult global economic conditions. Key Strategies & Plans included in the Report for each OEM: 1. Product Portfolio ...
June 2013
90 pages
